Advances in Glucagon like peptide-2 therapy. physiology, current indications and future directions

The treatment paradigm for pediatric patients with short bowel syndrome (SBS) and intesti- nal failure (IF) has changed significantly over recent years; the development of dedicated IF teams, refinements in PN and surgical treatments have greatly improved survival. The majority of SBS patients undergo intestinal adaptation such that nutrient absorption from enteral feeds increases and the child can come off of PN. This “adaptation” or upregulation in nutrient absorptive capacity is still poorly understood; the enteric hormone Glucagon like peptide 2 (GLP-2) appears to be a key regulator in this process.
Source: Seminars in Pediatric Surgery - Category: Pediatrics Authors: Source Type: research